 Home > Biochemistry News > Biotechnology News > Reindeer Medical and Cinda Bio will report the latest research results of BCMA CAR-T (CT103A) at the 2021 ASH annual meeting

Reindeer Medical and Cinda Bio will report the latest research results of BCMA CAR-T (CT103A) at the 2021 ASH annual meeting

 Last Update: 2022-01-01
 Source: Internet
 Author: User

Tags

media drug

abstract star

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Nanjing, Shanghai and San Francisco, November 10, 2021 /PRNewswire/ - Reindeer Medical, an innovative biopharmaceutical company in the clinical stage dedicated to the development and industrialization of cell therapy and antibody drugs, today announced that it will be 63rd in 2021 At the American Society of Hematology (ASH) annual meeting, it presented the fully human B cell mature antigen ( BMCA) The latest phase 1/2 registered clinical study results of the chimeric antigen receptor autologous T cell (CAR-T) therapy (reindeer medical research and development code: CT103A, Cinda Biologics research and development code: IBI326) (abstract number: 547)

This oral report will show the latest clinical data of the Phase 1/2 clinical study (ChiCTR1800018137) of CT103A in the treatment of relapsed/refractory multiple myeloma (RRMM) at 13 centers, including more trials in a longer follow-up period The more complete safety and efficacy results of the patient, as well as the pharmacokinetic data of CT103A

Abstract Title: Phase 1/2 clinical study of fully human B-cell mature antigen-specific CAR-T cells (CT103A) in the treatment of patients with relapsed/refractory multiple myeloma Report type: Oral report Abstract number 547 Conference topic: 704.

At present, CT103A (IIT) clinical research initiated by domestic researchers-the safety and effectiveness of CT103A cell infusion in the treatment of relapsed/refractory plasma cell tumors, a single-center, open phase I clinical study has completed 23 cases Follow-up for at least 2 years after infusion; Registered clinical study-fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A) for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) Phase Ib/II clinical study (ChiCTR1800018137) is under development

About multiple myeloma (MM)

Multiple myeloma (MM) is one of the most common blood cancers.

The number of new cases of MM in the United States increased from 30,300 in 2016 to 32,300 in 2020, and is expected to increase to 37,800 in 2025

About CT103A (BCMA CAR-T)

CT103A is an innovative product jointly developed by Reindeer Medical and Xinda Biopharmaceuticals

About Reindeer Medical

Reindeer Medical is an innovative biopharmaceutical company focusing on cell therapy and antibody drug development and industrialization

With a strong executive management team, rich product pipeline, unique innovative R&D and business model, Reindeer Medical is committed to becoming an influential innovative pharmaceutical company in the industry, and will promote innovative drugs that truly solve clinical pain points and have market competitiveness.

Source: Reindeer Medical

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.